4.7 Article

Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4

期刊

ISCIENCE
卷 24, 期 4, 页码 -

出版社

CELL PRESS
DOI: 10.1016/j.isci.2021.102388

关键词

-

资金

  1. NIH [RO1 CA174798, 5P50 CA140388, P30 CA16672]
  2. Prostate Cancer Foundation
  3. Cancer Prevention and Research Institute of Texas [CPRIT RP150179, RP190252]
  4. University of Texas MD Anderson Sister Institute Network Fund
  5. University of Texas MD Anderson Sister Institute Moonshot Program

向作者/读者索取更多资源

This study elucidated the signaling pathways and key molecules involved in prostate cancer-induced cell type transition in bone metastasis, providing potential targets for therapeutic intervention.
Cell type transition occurs during normal development and under pathological conditions. In prostate cancer bone metastasis, prostate cancer-secreted BMP4 induces endothelial cell-to-osteoblast (EC-to-OSB) transition. Such tumor-induced stromal reprogramming supports prostate cancer progression. We delineate signaling pathways mediating EC-to-OSB transition using EC lines 2H11 and SVR. We found that BMP4-activated pSmad1-Notch-Hey1 pathway inhibits EC migration and tube formation. BMP4-activated GSK3b-bcatenin-Slug pathway stimulates Osx expression. In addition, pSmad1-regulated Dlx2 converges with the Smad1 and beta-catenin pathways to stimulate osteocalcin expression. By co-expressing-Osx, Dlx2, Slug and Hey1, wewere able to achieve EC-to-OSB transition, leading to bone matrix mineralization in the absence of BMP4. In human prostate cancer bone metastasis specimens and MDA-PCa-118b and C4-2b-BMP4 osteogenic xenografts, immunohistochemical analysis showed that b-catenin and pSmad1 are detected in activated osteoblasts rimming the tumor-induced bone. Our results elucidated the pathways and key molecules coordinating prostate cancer-induced stromal programming and provide potential targets for therapeutic intervention.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据